Eli Lilly’s drug tirzepatide, sold under the names Mounjaro for diabetes and Zepbound for weight loss, improved symptoms in heart failure patients with obesity, the company said Thursday.

Tirzepatide demonstrated statistically significant improvements in both primary endpoints with a reduction in the risk of heart failure outcomes, assessed as a composite endpoint, and improvements ...

Eli Lilly and Company announced Thursday morning that its GLP-1 drug tirzepatide cut the risk of heart failure by 38% in a Phase 3 trial. Tirzepatide – better known by its name brands Mounjaro for ...

Tirzepatide significantly lowers hospitalization and death risks in heart failure patients The drug shows potential for managing heart failure with preserved ejection fraction Participants ...

A three-year study of tirzepatide – a medication approved ... such as high blood pressure or heart disease. Like similar drugs, it’s used as a shot patients give themselves once a week and ...

The drug company says Tirzepatide cuts the risk of progression to diabetes by 94% in adults with pre-diabetes and obesity.

New research finds that people who catch up on z’s on their days off can cut their risk of heart disease by up to 20%. “Sufficient compensatory sleep is linked to a lower risk of heart disease ...

“Sufficient compensatory sleep is linked to a lower risk of heart disease,” study coauthor Yanjun Song said in a news release ahead of the meeting. “The association becomes even more ...